Ovarian cancer biomarkers for molecular biosensors and translational medicine

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Cho KR, Shih IeM. Ovarian cancer. Annu. Rev. Pathol.4, 287–313 (2009).
   PubMed Web of Science ®Google Scholar
• Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. J. Ovarian Res.3, 8 (2010).
   PubMedGoogle Scholar
• Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer9(6), 415–428 (2009).
   PubMed Web of Science ®Google Scholar
• Suh KS, Remache YK, Patel JS et al. Informatics-guided procurement of patient samples for biomarker discovery projects in cancer research. Cell Tissue Bank10(1), 43–48 (2009).
   PubMedGoogle Scholar
• Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. Int. J. Gynecol. Cancer19(2), 230–236 (2009).
   PubMed Web of Science ®Google Scholar
• van Nagell Jr JR, DePriest PD, Ueland FR et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer109(9), 1887–1896 (2007).
   PubMedGoogle Scholar
• Murta EFC, Nomelini RS. Early diagnosis and predictors of malignancy of adnexal masses. Curr. Opin. Obstet. Gynecol.18(1), 14–19 (2006).
   PubMed Web of Science ®Google Scholar
• Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr. Oncol. Rep.3(1), 27–32 (2001).
   PubMedGoogle Scholar
• Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol. Cell. Endocrinol.202(1–2), 97–99 (2003).
   PubMed Web of Science ®Google Scholar
• Cho KR. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch. Pathol. Lab. Med.133(11), 1775–1781 (2009).
   PubMedGoogle Scholar
• Maggino T, Gadducci A. Serum markers as prognostic factors in epithelial ovarian cancer: an overview. Eur. J. Gynaecol. Oncol.21(1), 64–69 (2000).
   PubMedGoogle Scholar
• Bast Jr. RC, Urban N, Shridhar V et al. Early detection of ovarian cancer: promise and reality. Cancer Treat. Res.107, 61–97 (2002).
   PubMedGoogle Scholar
• Tuxen MK, Sölétormos G, Dombernowsky P. Serum tumor marker CA-125 for monitoring ovarian cancer during follow-up. Scand. J. Clin. Lab. Invest.62(3), 177–188 (2002).
   PubMed Web of Science ®Google Scholar
• Mann WJ, Patsner B, Cohen H, Loesch M. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J. Natl Cancer Inst.80(3), 208–209 (1988).
   PubMedGoogle Scholar
• Høgdall E. Cancer antigen 125 and prognosis. Curr. Opin. Obstet. Gynecol.20(1), 4–8 (2008).
   PubMed Web of Science ®Google Scholar
• Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA-125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol.142(2), 99–105 (2008).
   PubMedGoogle Scholar
• Kui Wong N, Easton RL, Panico M et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA-125. J. Biol. Chem.278(31), 28619–28634 (2003).
   PubMed Web of Science ®Google Scholar
• Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA-125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur. J. Radiol.71(1), 164–174 (2009).
   PubMedGoogle Scholar
• Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer100(8), 1315–1319 (2009).
   PubMed Web of Science ®Google Scholar
• Karp PD, Paley S, Krieger CJ, Zhang P. An evidence ontology for use in pathway/genome databases. Pac. Symp. Biocomput.190–201 (2004).
   PubMedGoogle Scholar
• Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol.164(5), 1511–1518 (2004).
   PubMed Web of Science ®Google Scholar
• Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med.5(12), e232 (2008).
   PubMed Web of Science ®Google Scholar
• Im SS, Gordon AN, Buttin BM et al. Validation of referral guidelines for women with pelvic masses. Obstet. Gynecol.105(1), 35–41 (2005).
   PubMedGoogle Scholar
• Cramer DW. Phase III validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO screening trial. Presented at: Proceedings of AACR, AACR 100th Annual Meeting. Denver, CO, USA, 18–22 April 2009.
   Google Scholar
• Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol. Oncol.96(1), 77–83 (2005).
   PubMed Web of Science ®Google Scholar
• Pyle-Chenault RA, Stolk JA, Molesh DA et al. VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol.26(5), 245–257 (2005).
   PubMedGoogle Scholar
• Attur MG, Palmer GD, Al-Mussawir HE et al. F-spondin, a neuroregulatory protein, is up-regulated in osteoarthritis and regulates cartilage metabolism via TGF-β activation. FASEB J.23(1), 79–89 (2009).
   PubMed Web of Science ®Google Scholar
• Miszczak-Zaborska E, Wójcik-Krowiranda K, Kubiak R, Bieńkiewicz A, Bartkowiak J. The activity of thymidine phosphorylase as a new ovarian tumor marker. Gynecol. Oncol.94(1), 86–92 (2004).
   PubMedGoogle Scholar
• Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med. Res. Rev.29(6), 903–953 (2009).
   PubMed Web of Science ®Google Scholar
• Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst.93(19), 1458–1464 (2001).
   PubMed Web of Science ®Google Scholar
• López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer7(10), 800–808 (2007).
   PubMed Web of Science ®Google Scholar
• Costa FP, Batista Junior EL, Zelmanowicz A et al. Prostasin, a potential tumor marker in ovarian cancer – a pilot study. Clinics (Sao Paulo)64(7), 641–644 (2009).
   PubMedGoogle Scholar
• Acar A, Onan A, Coskun U et al. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med. Oncol.25(3), 279–283 (2008).
   PubMed Web of Science ®Google Scholar
• Badgwell D, Lu Z, Cole L et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free β subunit and urinary hCG β core fragment. Gynecol. Oncol.106(3), 490–497 (2007).
   PubMed Web of Science ®Google Scholar
• Baron AT, Cora EM, Lafky JM et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev.12, 103–113 (2003).
   PubMed Web of Science ®Google Scholar
• Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet. Gynecol.82(6), 946–950 (1993).
   PubMedGoogle Scholar
• Bose CK. Role of nerve growth factor and FSH receptor in epithelial ovarian cancer. Reprod. Biomed. Online11, 194–197 (2005).
   PubMedGoogle Scholar
• Feldkamper M, Enderle-Schmitt U, Hackenberg R, Schulz KD. Urinary excretion of growth factors in patients with ovarian cancer. Eur. J. Cancer30A(12), 1851–1858 (1994).
   PubMedGoogle Scholar
• Zeren T, Inan S, Seda Vatansever H, Ekerbicer N, Sayhan S. Significance of tyrosine kinase activity on malign transformation of ovarian tumors: a comparison between EGF-R and TGF-α. Acta Histochem.110(3), 256–263 (2008).
   PubMedGoogle Scholar
• Gr öschl M. The physiological role of hormones in saliva. Bioessays31(8), 843–852 (2009).
   PubMedGoogle Scholar
• Drenberg CD, Saunders BO, Wilbanks GD et al. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol. Oncol.117(1), 117–124 (2010).
   PubMedGoogle Scholar
• Tabruyn SP, Mémet S, Avé P et al. NF-κB activation in endothelial cells is critical for the activity of angiostatic agents. Mol. Cancer Ther.8(9), 2645–2654 (2009).
   PubMed Web of Science ®Google Scholar
• Mu W, Long DA, Ouyang X et al. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am. J. Physiol. Renal Physiol.296(1), F145–F152 (2009).
   Google Scholar
• Perri SR, Annabi B, Galipeau J. Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. FASEB J.21(14), 3928–3936 (2007).
   PubMedGoogle Scholar
• Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv. Exp. Med. Biol.622, 15–21 (2008).
   PubMed Web of Science ®Google Scholar
• Hernádi Z, Molnár V, Juhász B, Pólka R, Margitai B. Predictive value of the tumor marker combination CA-125 and β-2-microglobulin in ovarian cancer. Zentralbl. Gynakol.114(1), 6–9 (1992).
   PubMedGoogle Scholar
• Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res.64, 5882–5890 (2004).
   PubMed Web of Science ®Google Scholar
• Edgell T, Martin-Roussety G, Barker G et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J. Cancer Res. Clin. Oncol.136(7), 1079–1088 (2010).
   PubMed Web of Science ®Google Scholar
• Lee G, Ng HT. Clinical evaluations of a new ovarian cancer marker, COX-1. Int. J. Gynaecol. Obstet.49(Suppl.), S27–S32 (1995).
   PubMedGoogle Scholar
• Nozawa S, Aoki D, Yajima M et al. CA54/61 as a marker for epithelial ovarian cancer. Cancer Res.52(5), 1205–1209 (1992).
   PubMedGoogle Scholar
• Lambeck AJ, Crijns AP, Leffers N et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin. Cancer Res.13(8), 2385–2391 (2007).
   PubMed Web of Science ®Google Scholar
• Yabushita H, Sawaguchi K, Hieda S et al. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin. Nippon Sanka Fujinka Gakkai Zasshi41(2), 217–224 (1989).
   PubMedGoogle Scholar
• Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene21, 2768–2773 (2002).
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res.63, 3695–3700 (2003).
   PubMed Web of Science ®Google Scholar
• Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol.31, 113–119 (2010).
   PubMed Web of Science ®Google Scholar
• Li J, Dowdy S, Tipton T et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn.9(6), 555–566 (2009).
   PubMed Web of Science ®Google Scholar
• Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol.28(13), 2159–2166 (2010).
   PubMed Web of Science ®Google Scholar
• Anderson GL, McIntosh M, Wu L et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. J. Natl Cancer Inst.102, 26–38 (2010).
   PubMed Web of Science ®Google Scholar
• Drapkin R, von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res.65, 2162–2169 (2005).
   PubMed Web of Science ®Google Scholar
• Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl. Immunohistochem. Mol. Morphol.12(2), 122–126 (2004).
   PubMedGoogle Scholar
• Kato N, Toukairin M, Asanuma I, Motoyama T. Immunocytochemistry for hepatocyte nuclear factor-1β (HNF-1β): a marker for ovarian clear cell carcinoma. Diagn. Cytopathol.35(4), 193–197 (2007).
   PubMedGoogle Scholar
• Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol.163(6), 2503–2512 (2003).
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Goldberg I, Weisz B et al. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol. Oncol.82(1), 99–104 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Petrillo M, Carbone A et al. Prognostic role of topoisomerase-II a in advanced ovarian cancer patients. Br. J. Cancer98(12), 1910–1915 (2008).
   PubMedGoogle Scholar
• Borgfeldt C, Bendahl PO, Fernö M, Casslén B. High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer. Gynecol. Oncol.91(1), 112–117 (2003).
   PubMedGoogle Scholar
• Høgdall EV, Ringsholt M, Høgdall CK et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer9, 8 (2009).
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int. J. Gynecol. Cancer17(4), 798–807 (2007).
   PubMed Web of Science ®Google Scholar
• Engels K, du Bois A, Harter P et al. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J. Clin. Pathol.62(5), 448–454 (2009).
   PubMedGoogle Scholar
• Goldberg I, Davidson B, Reich R et al. av integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin. Cancer Res.7(12), 4073–4079 (2001).
   PubMedGoogle Scholar
• Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS. αVβ6 integrin-A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem.50(10), 1371–1380 (2002).
   PubMedGoogle Scholar
• Lee JH, Kim SH, Lee ES, Kim YS. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol. Rep.22(5), 1149–1156 (2009).
   PubMedGoogle Scholar
• Heimburg S, Oehler MK, Papadopoulos T, Caffier H, Kristen P, Dietl J. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res.19(4A), 2527–2529 (1999).
   PubMedGoogle Scholar
• Kapitanovic S, Spaventi R, Vujsic S et al.nm23-H1 gene expression in ovarian tumors – a potential tumor marker. Anticancer Res.15(2), 587–590 (1995).
   PubMedGoogle Scholar
• Hogdall EV, Christensen L, Kjaer SK et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer98, 66–73 (2003).
   PubMed Web of Science ®Google Scholar
• van Dalen A, Favier J, Hallensleben E et al. Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur. J. Gynaecol. Oncol.30, 609–615 (2009).
   PubMedGoogle Scholar
• Hata K, Dhar DK, Kanasaki H et al. Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res.23, 1907–1912 (2003).
   PubMedGoogle Scholar
• Zhao C, Annamalai L, Guo C et al. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia9, 1–7 (2007).
   PubMed Web of Science ®Google Scholar
• Hogdall CK, Norgaard-Pedersen B, Mogensen O. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res.22, 1765–1768 (2002).
   PubMed Web of Science ®Google Scholar
• Chen FC, Oskay-Ozcelik G, Buhling KJ et al. Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res.29, 1575–1578 (2009).
   PubMedGoogle Scholar
• Mustea A, Pirvulescu C, Konsgen D et al. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine42, 77–84 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto A, Nikaido T, Ochiai K et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res.11(16), 6030–6039 (2005).
   PubMed Web of Science ®Google Scholar
• Inaba T, Ino K, Kajiyama H et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol.115(2), 185–192 (2009).
   PubMed Web of Science ®Google Scholar
• Lee P, Rosen DG, Zhu C et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol. Oncol.96(3), 671–677 (2005).
   PubMedGoogle Scholar
• Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int. J. Gynecol. Cancer19(4), 620–627 (2009).
   PubMedGoogle Scholar
• Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin. Exp. Metastasis20(2), 161–169 (2003).
   PubMedGoogle Scholar
• Kristiansen G, Denkert C, Schlüns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am. J. Pathol.161(4), 1215–1221 (2002).
   PubMed Web of Science ®Google Scholar
• Suh KS, Crutchley JM, Koochek A et al. Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers. Clin. Cancer Res.13(1), 121–131 (2007).
   PubMedGoogle Scholar
• Davidson B, Alejandro E, Flørenes VA et al. Granulin–epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer100(10), 2139–2147 (2004).
   PubMed Web of Science ®Google Scholar
• Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. c-Ets1 is a promising marker in epithelial ovarian cancer. Int. J. Mol. Med.9(3), 287–292 (2002).
   PubMedGoogle Scholar
• Borgoño CA, Kishi T, Scorilas A et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin. Cancer Res.12(5), 1487–1493 (2006).
   PubMed Web of Science ®Google Scholar
• Scorilas A, Borgoño CA, Harbeck N et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J. Clin. Oncol.22(4), 678–685 (2004).
   PubMed Web of Science ®Google Scholar
• Borgoño CA, Fracchioli S, Yousef GM et al. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int. J. Cancer106(4), 605–610 (2003).
   PubMed Web of Science ®Google Scholar
• McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin. Cancer Res.13(15 Pt 1), 4422–4428 (2007).
   PubMed Web of Science ®Google Scholar
• Luo LY, Katsaros D, Scorilas A et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res.63(4), 807–811 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffman BR, Katsaros D, Scorilas A et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer87(7), 763–771 (2002).
   PubMedGoogle Scholar
• Psyrri A, Kountourakis P, Scorilas A et al. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann. Oncol.19(7), 1271–1277 (2008).
   PubMed Web of Science ®Google Scholar
• Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br. J. Cancer96(2), 362–372 (2007).
   PubMedGoogle Scholar
• Ohishi Y, Oda Y, Basaki Y et al. Expression of β-tubulin isotypes in human primary ovarian carcinoma. Gynecol. Oncol.105(3), 586–592 (2007).
   PubMed Web of Science ®Google Scholar
• Aldovini D, Demichelis F, Doglioni C et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int. J. Cancer119(8), 1920–1926 (2006).
   PubMedGoogle Scholar
• Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res.20(2B), 1061–1067 (2000).
   PubMed Web of Science ®Google Scholar
• Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-21 assay in patients with ovarian cancer. Int. J. Gynecol. Cancer11, 277–282 (2001).
   PubMed Web of Science ®Google Scholar
• Yan X, Yin J, Yao H, Mao N, Yang Y, Pan L. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res.70, 1616–1624 (2010).
   PubMedGoogle Scholar
• Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur. J. Cancer34(6), 845–850 (1998).
   PubMedGoogle Scholar
• Pan HS, Lee SL, Huang LW, Chen YK. Combined positron emission tomography–computed tomography and tumor markers for detecting recurrent ovarian cancer. Arch. Gynecol. Obstet. DOI: 10.1007/s00404-010-1404-6 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Mangala LS, Zuzel V, Schmandt R et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin. Cancer Res.15(11), 3770–3780 (2009).
   PubMed Web of Science ®Google Scholar
• Gronlund B, Høgdall EV, Christensen IJ et al. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA-125). Int. J. Biol. Markers21(3), 141–148 (2006).
   PubMedGoogle Scholar
• Morikawa T, Kobayashi S, Ogino T et al. [An epithelial myoepithelial carcinoma of the parotid gland]. Gan No Rinsho36(12), 2153–2157 (1990).
   PubMedGoogle Scholar
• van Niekerk CC, Vooijs P, Casparie-van Velsen IJ, Poels LG. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies. Cancer Detect. Prev.21(3), 247–257 (1997).
   PubMedGoogle Scholar
• Tamakoshi K, Kikkawa F, Hasegawa N et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125. Gynecol. Obstet. Invest.39(2), 125–129 (1995).
   PubMedGoogle Scholar
• Suzuki M, Sekiguchi I, Ohwada M, Aida I, Tamada T. [Clinical value of a new serum tumor marker CA602 in ovarian cancers]. Nippon Gan Chiryo Gakkai Shi25(7), 1454–1460 (1990).
   PubMedGoogle Scholar
• Nozawa S, Yajima M, Sakuma T et al. Cancer-associated galactosyltransferase as a new tumor marker for ovarian clear cell carcinoma. Cancer Res.50(3), 754–759 (1990).
   PubMedGoogle Scholar
• Warwas M, Haczyńska H, Gerber J, Nowak M. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur. J. Clin. Chem. Clin. Biochem.35(4), 301–304 (1997).
   PubMedGoogle Scholar
• Nozawa S, Udagawa Y, Ito K et al. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer – with special reference to the discrimination between ovarian cancer and endometriosis]. Gan To Kagaku Ryoho21(4), 507–516 (1994).
   PubMedGoogle Scholar
• Nozawa S, Udagawa Y, Ito K, Susumu N, Sasaki H, Aoki D. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (first report) – preclinical study of GAT assay kit and clinical study of normal level]. Gan To Kagaku Ryoho20(2), 271–277 (1993).
   PubMedGoogle Scholar
• Nozawa S, Udagawa Y, Ito K, Susumu N, Sasaki H, Aoki D. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report) – clinical significance of GAT and comparison with other tumor markers]. Gan To Kagaku Ryoho20(2), 279–285 (1993).
   PubMedGoogle Scholar
• Shimizu Y, Akagaki E, Hirota K et al. [Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects]. Nippon Sanka Fujinka Gakkai Zasshi38(4), 554–560 (1986).
   PubMedGoogle Scholar
• Bäckström T, Mählck CG, Kjellgren O. Progesterone as a possible tumor marker for “nonendocrine” ovarian malignant tumors. Gynecol. Oncol.16(1), 129–138 (1983).
   PubMedGoogle Scholar
• Onsrud M, Shabana A, Austgulen R, Nustad K. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol. Oncol.57(2), 183–187 (1995).
   PubMedGoogle Scholar